Understanding Real-World Patient Characterization And Safety Outcomes Of DEXTENZA

This real-world study evaluated the postoperative safety and utilization patterns of the intracanalicular dexamethasone insert (DEXTENZA) in ocular surgery using data from the American Academy of Ophthalmology IRIS^® Registry. In collaboration with Verana Health, Ocular Therapeutix analyzed de-identified electronic health records from over 3.7 million cataract surgeries performed between June 2019 and November 2022, identifying a final cohort of 10,313 eyes treated with DEXTENZA.

Using natural language processing to extract structured insights from EHR notes, the study characterized patient demographics, ocular comorbidities, and concomitant procedures, including minimally invasive glaucoma surgeries (MIGS). Findings revealed that postoperative inflammatory events such as anterior uveitis and corneal edema occurred less frequently in real-world DEXTENZA recipients compared to clinical trial data. The extended analysis confirms DEXTENZA’s favorable safety profile across a broader surgical spectrum and informs ongoing postmarketing surveillance and clinical integration strategies.